Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Cefotaxime and ceftriaxone have proven to be effective in pyogenic infections of the central nervous system. Since in some bacterial central nervous system infections the blood-cerebrospinal fluid (CSF) barrier is either minimally impaired or recovers in the course of the illness, we studied the penetration of both antibiotics in the absence of inflamed meninges. Patients who had undergone external ventriculostomies for noninflammatory occlusive hydrocephalus received either cefotaxime (2 g/30 min) or ceftriaxone (2 g/30 min) to treat extracerebral infections. Serum and CSF were drawn repeatedly after the first dose. With ceftriaxone, they were also drawn after the last dose. The concentrations of cefotaxime, its metabolite desacetylcefotaxime, and ceftriaxone were determined by high-performance liquid chromatography with UV detection. Maximum concentrations of cefotaxime in CSF were reached 0.5 to 8 h (median = 3 h; n = 6) after the end of the infusion and ranged from 0.14 to 1.81 mg/liter (median = 0.44 mg/liter; n = 6). Maximum levels of ceftriaxone in CSF ranging from 0.18 to 1.04 mg/liter (median = 0.43 mg/liter; n = 5) were seen 1 to 16 h (median = 12 h; n = 5) after the infusion. The elimination half-life of cefotaxime in CSF was 5.0 to 26.9 h (median = 9.3 h; n = 5), and that of ceftriaxone was 15.7 to 18.4 h (median = 16.8 h; n = 3). It is concluded that after a single dose of 2 g, maximal concentrations of cefotaxime and ceftriaxone in CSF do not differ substantially. The long elimination half-lives guarantee uniform concentrations in CSF. These concentrations reliably inhibit highly susceptible bacteria but cannot be relied on to inhibit staphylococci and penicillin G-resistant Streptococcus pneumoniae.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efflux of radiolabeled polyethylene glycols and albumin from rat brain
Cserr, H. F., Cooper, D. N., Suri, P. K., & Patlak, C. S. (1981) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1981.240.4.f319 · Cited by 323
Bulk flow of brain interstitial fluid under normal and hyperosmolar conditions
Rosenberg, G. A., Kyner, W. T., & Estrada, E. (1980) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1980.238.1.f42 · Cited by 210
Schlech, W. F. (1985) · JAMA · doi:10.1001/jama.1985.03350360075022 · Cited by 2
Cited by
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
Nau, R., Sörgel, F., & Eiffert, H. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00007-10 · Cited by 1,026
Self-citationLee, S.-G., Su, Z.-Z., Emdad, L., Gupta, P., Sarkar, D., Borjabad, A., Volsky, D. J., & Fisher, P. B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707697200 · Cited by 317
SHEN, D., ARTRU, A., & ADKISON, K. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.07.011 · Cited by 286
Miller, B. R., Dorner, J. L., Shou, M., Sari, Y., Barton, S. J., Sengelaub, D. R., Kennedy, R. T., & Rebec, G. V. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.02.004 · Cited by 280
“It is also relevant that 3.5 μmol/L ceftriaxone, the EC50 required to increase GLT1 expression (Rothstein et al., 2005), is comparable to levels of ceftriaxone found in the central nervous system of patients undergoing therapy for meningitis (0.3 to 6 μmol/L) (Nau et al., 1993).”
BackgroundInfluentialNeuroprotective agents for clinical trials in ALS: A systematic assessment
Traynor, B. J., Bruijn, L., Conwit, R., Beal, F., O’Neill, G., Fagan, S. C., & Cudkowicz, M. E. (2006) · Neurology · doi:10.1212/01.wnl.0000223353.34006.54 · Cited by 193
Pharmacological Induction of Ischemic Tolerance by Glutamate Transporter-1 (EAAT2) Upregulation
Chu, K., Lee, S.-T., Sinn, D.-I., Ko, S.-Y., Kim, E.-H., Kim, J.-M., Kim, S.-J., Park, D.-K., Jung, K.-H., Song, E.-C., et al. (2007) · Stroke · doi:10.1161/01.str.0000252091.36912.65 · Cited by 188
The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Blasco, H., Mavel, S., Corcia, P., & Gordon, P. H. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140916120118 · Cited by 164
“Of -lactam antibiotics identified in the high throughput screen assessing potential neuroprotective activity in ALS [42], ceftriaxone was selected for human studies because of its good CNS penetration and longer halflife than other agents in its class [240].”
BackgroundLeung, T. C. H., Lui, C. N. P., Chen, L. W., Yung, W. H., Chan, Y. S., & Yung, K. K. L. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200072h · Cited by 78
Ceftriaxone Blocks the Polymerization of α-Synuclein and Exerts Neuroprotective Effects in Vitro
Ruzza, P., Siligardi, G., Hussain, R., Marchiani, A., Islami, M., Bubacco, L., Delogu, G., Fabbri, D., Dettori, M. A., Sechi, M., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn400149k · Cited by 70
Ho, S.-C., Hsu, C.-C., Pawlak, C. R., Tikhonova, M. A., Lai, T.-J., Amstislavskaya, T. G., & Ho, Y.-J. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.04.022 · Cited by 65
Hsu, C.-Y., Hung, C.-S., Chang, H.-M., Liao, W.-C., Ho, S.-C., & Ho, Y.-J. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.023 · Cited by 63
The Role of the Microbiota–Gut–Brain Axis and Antibiotics in ALS and Neurodegenerative Diseases
Obrenovich, M., Jaworski, H., Tadimalla, T., Mistry, A., Sykes, L., Perry, G., & Bonomo, R. (2020) · Microorganisms · doi:10.3390/microorganisms8050784 · Cited by 62
“More arguments for oxidative stress and mitochondrial protectants [75,76] in ALS comes from the exploration of mitochondrial superoxide dismutase (mSOD)-induced defective mitochondria, which is associated with the pathogenesis of ALS and other neurodegenerative diseases as evidenced by mitochondrial swelling, giant mi…”
BackgroundTai, C.-H., Bellesi, M., Chen, A.-C., Lin, C.-L., Li, H.-H., Lin, P.-J., Liao, W.-C., Hung, C.-S., Schwarting, R. K., & Ho, Y.-J. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.02.020 · Cited by 34
Metadata
- Authors
- Nau, R., Prange, H. W., Muth, P., Mahr, G., Menck, S., Kolenda, H., & Sörgel, F.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1993-07
- Volume
- 37
- Issue
- 7
- Pages
- 1518-1524
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2169587049
- Cited by
- 141
- References
- 3
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.